Company intelligence / Profile preview
OGD2 Pharma
Nantes, Pays de la Loire, Franceorpha.net ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
OGD2 Pharma specializes in O-acetylated GD2 targeting to avoid neurotoxicity associated with standard anti-GD therapies. Preclinical evidence has been shown for glioblastoma and breast cancer applications using patient-derived xenograft models. The company targets both orphan indications (neuroblastoma) and major cancers through a CSC-directed approach.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on OGD2 Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OGD2 Pharma.